Your browser doesn't support javascript.
Predominance of antibody-resistant SARS-CoV-2 variants in vaccine breakthrough cases from the San Francisco Bay Area, California.
Servellita, Venice; Morris, Mary Kate; Sotomayor-Gonzalez, Alicia; Gliwa, Amelia S; Torres, Erika; Brazer, Noah; Zhou, Alicia; Hernandez, Katherine T; Sankaran, Madeline; Wang, Baolin; Wong, Daniel; Wang, Candace; Zhang, Yueyuan; Reyes, Kevin R; Glasner, Dustin; Deng, Xianding; Streithorst, Jessica; Miller, Steve; Frias, Edwin; Rodgers, Mary; Cloherty, Gavin; Hackett, John; Hanson, Carl; Wadford, Debra; Philip, Susan; Topper, Scott; Sachdev, Darpun; Chiu, Charles Y.
  • Servellita V; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Morris MK; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Sotomayor-Gonzalez A; Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
  • Gliwa AS; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Torres E; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Brazer N; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Zhou A; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Hernandez KT; Color Genomics, Inc., Burlingame, CA, USA.
  • Sankaran M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Wang B; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Wong D; Color Genomics, Inc., Burlingame, CA, USA.
  • Wang C; San Francisco Department of Public Health, San Francisco, CA, USA.
  • Zhang Y; San Francisco Department of Public Health, San Francisco, CA, USA.
  • Reyes KR; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Glasner D; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Deng X; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Streithorst J; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Miller S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Frias E; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Rodgers M; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Cloherty G; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Hackett J; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Hanson C; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Wadford D; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Philip S; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Topper S; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Sachdev D; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Chiu CY; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Nat Microbiol ; 7(2): 277-288, 2022 02.
Artículo en Inglés | MEDLINE | ID: covidwho-1616987
Preprint
Este artículo de revista científica es probablemente basado en un preprint previamente disponible, por medio del reconocimiento de similitud realizado por una máquina. La confirmación humana aún está pendiente.
Ver preprint
ABSTRACT
Associations between vaccine breakthrough cases and infection by different SARS coronavirus 2 (SARS-CoV-2) variants have remained largely unexplored. Here we analysed SARS-CoV-2 whole-genome sequences and viral loads from 1,373 persons with COVID-19 from the San Francisco Bay Area from 1 February to 30 June 2021, of which 125 (9.1%) were vaccine breakthrough infections. Vaccine breakthrough infections were more commonly associated with circulating antibody-resistant variants carrying ≥1 mutation associated with decreased antibody neutralization (L452R/Q, E484K/Q and/or F490S) than infections in unvaccinated individuals (78% versus 48%, P = 1.96 × 10-8). Differences in viral loads were non-significant between unvaccinated and fully vaccinated cases overall (P = 0.99) and according to lineage (P = 0.09-0.78). Symptomatic vaccine breakthrough infections had comparable viral loads (P = 0.64), whereas asymptomatic breakthrough infections had decreased viral loads (P = 0.023) compared with infections in unvaccinated individuals. In 5 cases with serial samples available for serologic analyses, vaccine breakthrough infections were found to be associated with low or undetectable neutralizing antibody levels attributable to an immunocompromised state or infection by an antibody-resistant lineage. Taken together, our results show that vaccine breakthrough infections are overrepresented by antibody-resistant SARS-CoV-2 variants, and that symptomatic breakthrough infections may be as efficient in spreading COVID-19 as unvaccinated infections, regardless of the infecting lineage.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Vacuna BNT162 / Anticuerpos Antivirales Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas / Variantes Límite: Adolescente / Adulto / Anciano / Femenino / Humanos / Masculino / Middle aged / Young_adult País/Región como asunto: America del Norte Idioma: Inglés Revista: Nat Microbiol Año: 2022 Tipo del documento: Artículo País de afiliación: S41564-021-01041-4

Similares

MEDLINE
LILACS
LIS
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: SARS-CoV-2 / COVID-19 / Vacuna BNT162 / Anticuerpos Antivirales Tipo de estudio: Estudio de cohorte / Estudio observacional / Estudio pronóstico / Ensayo controlado aleatorizado Tópicos: Vacunas / Variantes Límite: Adolescente / Adulto / Anciano / Femenino / Humanos / Masculino / Middle aged / Young_adult País/Región como asunto: America del Norte Idioma: Inglés Revista: Nat Microbiol Año: 2022 Tipo del documento: Artículo País de afiliación: S41564-021-01041-4